Samsung Medical Center (SMC; President Park Seung-woo) announced on May 18 that it had signed an MOU on joint RD with REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) on May 11for mass production of cellular and gene therapy products based on Good Manufacturing Practices (GMP). Representatives of the SMC and REYON Pharmaceutical taking a picture at the MOU ceremony held at the Irwon Station campus of the SMC on May 11 The MOU ceremony was held at the Irwon Station campus of the SM...

REYON Pharmaceutical secured a base to advance into the European market by patenting the new drug candidate, RY-108 (iN-EYD), licensed from iNtRON Biotechnology last year, for antifungal use in Europe. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) announced on May 11 that the European Patent Office (EPO) had approved the patent application for pharmaceutical composition for the treatment of fungal infections caused by Cryptococcus and Candida fungi containing FK506 derivatives ...

REYON Pharmaceutical will start full-fledged production of plasmid DNA (pDNA) at the Chungju bio plant. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) announced on April 20 that it had signed a pDNA supply contract with INNOPEUTICS (CEO Kim Tae-gyun). REYON Pharmaceutical will produce the pDNA drug substance (DS) and drug product (DP) at the Chungju bio plant and supply it to INNOPEUTICS. The exact value of the contract was not disclosed as agreed between the two companies. REYO...

REYON Pharmaceutical officially unveiled the Chungju plants built with the aim of serving as global bio chemical drug production platforms and declared its commitment to becoming a global company. REYON Pharmaceutical (co-CEOs Jeong Soon-ok and Yoo Yong-hwan) held a completion ceremony on April 14 at the Chungju bio and chemical plants (Chungju plants) located in Daesowon-myeon, Chungju-si, Chungcheongbuk-do Province. [Celebrating the completion of construction of the Chungju plants on November...